Table 1 Characteristics of included studies
Author, year Strategy | Age Median | F/M (n/N) | TFD (Y) Median | Cytogenetic F/U/M | Drug dose mg/m2 | Prior therapy median | Prior therapy | Regimen | ORR | PFS (m) | OS (m) | Study design | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bort | Lena | ||||||||||||
Carfilzomib combinations for R/RMM | |||||||||||||
Berdeja 2015 [5] | 66 | 27/17 | – | – | 20/27/36/45 | 5 (1–10) | – | – | CP | 0.67 | 7.7 | – | Phase I/II |
Shan 2015 [6] | 64 | 12/20 | 5.9 | 10/−/− | 20/27/36/45/56 | 6 (2–12) | 31 | 32 | CPD | 0.50 | 7.2 | 20.6 | Phase I |
Berenson 2014(1) [7] | 67 | 13/25 | 4.2 | – | 20/27/36/45 | – | – | – | ► | 0.43 | 9.9 | 15.8 | Phase I/II |
Niesvizky 2013 [8] | 61.5 | 18/22 | 3.3 | 25/11/4 | 15/20/27 | 2 (1–3) | 30 | 28 | CRD | 0.62 | 10.2 | – | Phase Ib |
Papadopoulos 2015 [9] | 59.5 | 5/17 | 3.6 | 14/7/1 | 20/36/45/56/70 | 4(2–9) | 21 | – | CD | 0.55 | – | – | Phase I |
Stewart 2015 [10] | 64.0 | 181/215 | 3.0 | 48/147/201 | 20/27 | 2(1–3) | 261 | 79 | CRD | 0.87 | 26.3 | – | phase I/II |
Wang 2013 [11] | 61.5 | 36/48 | 3.1 | 57/22/5 | 20/27 | 2 (1–5) | 65 | 59 | CRD | 0.69 | 11.8 | – | Phase II |
Berenson 2014 (2) [12] | 63 | – | – | – | 20/45/56/70/88 | 1(1–2) | – | – | CD | 0.67 | – | – | Phase I/II |
Dimopoulos 2015 [13] | – | – | – | – | 20/56 | – | – | – | CD | 0.77 | – | – | Phase III |
Kaufman 2014 [14] | 64.5 | – | – | – | 20/36/45 | – | – | – | CP | 0.50 | 14.3 | – | Phase I |
Vesole 2015 [15] | 61 | 7/10 | 4 | 3/12/2 | 15/20/27 | 4 (1–9) | 17 | 16 | QUAD | 0.53 | 12 | – | Phase I |
Panobinostat combinations for R/RMM | |||||||||||||
Offidani 2012 [16] | 73 | 5/7 | – | – | 15 | – | 8 | 5 | PMT | 0.41 | 14.3 | – | Phase II |
65 | 10/9 | – | – | 10 | – | 16 | 9 | PMT | 0.37 | 14.3 | – | Phase II | |
Richardson 2013 [17] | 61 | 26/29 | 4.6 | 2/35/18 | 4 (2–11) | 55 | 54 | PBD | 0.34 | 5.4 | – | Phase II | |
San-Miguel 2013 [18] | 62 | 19/43 | – | – | 10/20/25/30 | 2 (1–10) | 39 | 28 | PBD | 0.52 | – | – | Phase Ib |
Kaufman 2014 [14] | 64.5 | – | – | – | 15-20 | – | – | – | CP | 0.50 | 14.3 | – | Phase I |
Berenson 2014 [19] | 65 | 15/25 | – | – | 20 | 4(1–16) | – | – | PM | 0.07 | – | – | Phase I/II |
San-Miguel 2014 [20] | 63 | 185/202 | – | – | 20 | – | 169 | 72 | PBD | 0.61 | 11 · 99 | 33 · 6 | Phase III |
Berdeja 2015 [5] | 66 | 27/17 | – | – | 20/30 | 5 (1–10) | – | – | CP | 0.67 | 7.7 | Phase I/II | |
Elotuzumab combinations for R/RMM | |||||||||||||
Jakubowiak 2012 [21] | 63 | 20/18 | 3.5 | – | 2.5/4.0/10/20 | 2(1–3) | 11 | 13 | EB | 0.48 | 9.46 | – | Phase I |
lonial 2012 [22] | 60 | – | 5.2 | 26/3/0 | 2.5/10/20 | 3(1–10) | 20 | 6 | ERD | 0.82 | – | Phase I | |
lonial 2015 [23] | 67 | – | – | – | 10 | 2(1–4) | 219 | 16 | ERD | 0.79 | 19.4 | – | Phase III |
Richardson 2015 [24] | 60.6 | 17/19 | 4.76 | 32/1/3 | 10 | – | 22 | – | ERD | 0.92 | 32 · 49 | – | Phase Ib-II |
63.3 | 13/24 | 4.96 | 27/3/7 | 20 | – | 22 | – | ERD | 0.76 | 25 · 00 | – | Phase Ib–II | |